Molecular Templates, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Net Income (Loss) Per Common Share (Tables)

Net Income (Loss) Per Common Share (Tables)

9 Months Ended

Sep. 30, 2013

Reconciliation of Numerator and Denominator

A reconciliation of the numerator and denominator used in the calculation is as follows (in thousands, except per share amounts):


	Three Months Ended September 30,						Nine months Ended September 30,
	2013			2012			2013			2012
Numerator:
Net income (loss) - basic	$	1,176		$	(991	)	$	(20,826	)	$	(99,523	)
Less: noncash income from change in fair value of common stock warrants		(6,379	)		(2,967	)		(557	)		—

Net loss - diluted		(5,203	)		(3,958	)		(21,383	)		(99,523	)

Denominator:
Weighted average common shares outstanding		58,542			55,654			57,362			53,516
Dilutive effect of warrants		5,019			8,751			2,509			—

Weighted-average common shares outstanding and potential dilutive common shares - diluted		63,561			64,405			59,871			53,516

Net income (loss) per share
Basic	$	0.02		$	(0.02	)	$	(0.36	)	$	(1.86	)

Diluted	$	(0.08	)	$	(0.06	)	$	(0.36	)	$	(1.86	)

Warrants, Options and Purchase Rights Excluded from Computation of Diluted Net Loss Per Share

The following outstanding warrants, options and purchase rights under the Company’s 2004 Employee Stock Purchase Plan were excluded from the computation of diluted net loss per share for the periods presented because including them would have had an antidilutive effect. The amounts disclosed below are prior to the application of the treasury stock method (in thousands):


	Three Months Ended September 30,				Nine months Ended September 30,
	2013		2012		2013		2012
Shares issuable upon exercise of warrants		—		—		4,034		11,726
Shares issuable upon exercise of stock options		6,560		5,129		6,560		5,129
Shares issuable related to the ESPP		28		48		28		48